Adam33 polymorphisms are associated with COPD and lung function in long-term tobacco smokers

Alireza Sadeghnejad*1, Jill A Ohar1, Siqun L Zheng1, David A Sterling2, Gregory A Hawkins1, Deborah A Meyers1 and Eugene R Bleecker*1

Address: 1Center for Human Genomics and Department of Medicine and Pediatrics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA and 2School of Public Health, Saint Louis University, St. Louis, Missouri, USA

Email: Alireza Sadeghnejad* - anejad@wfubmc.edu; Jill A Ohar - johar@wfubmc.edu; Siqun L Zheng - szheng@wfubmc.edu; David A Sterling - sterling@slu.edu; Gregory A Hawkins - ghawkins@wfubmc.edu; Deborah A Meyers - dmeyers@wfubmc.edu; Eugene R Bleecker* - ebleeck@wfubmc.edu

* Corresponding authors

Abstract

Background: Variation in ADAM33 has been shown to be important in the development of asthma and altered lung function. This relationship however, has not been investigated in the population susceptible to COPD; long term tobacco smokers. We evaluated the association between polymorphisms in ADAM33 gene with COPD and lung function in long term tobacco smokers.

Methods: Caucasian subjects, at least 50 year old, who smoked ≥ 20 pack-years (n = 880) were genotyped for 25 single nucleotide polymorphisms (SNPs) in ADAM33. COPD was defined as an FEV1/FVC ratio < 70% and percent-predicted (pp)FEV1 < 75% (n = 287). The control group had an FEV1/FVC ratio ≥ 70% and ppFEV1 ≥ 80% (n = 311) despite ≥ 20 pack years of smoking. Logistic and linear regressions were used for the analysis. Age, sex, and smoking status were considered as potential confounders.

Results: Five SNPs in ADAM33 were associated with COPD (Q-1, intronic: p < 0.003; S1, Ile → Val: p < 0.003; S2, Gly → Gly: p < 0.04; V-1 intronic: p < 0.002; V4, in 3’ untranslated region: p < 0.007). Q-1, S1 and V-1 were also associated with ppFEV1, FEV1/FVC ratio and ppFEF25–75 (p values 0.001 – 0.02). S2 was associated with FEV1/FVC ratio (p < 0.05). The association between S1 and residual volume revealed a trend toward significance (p value < 0.07). Linkage disequilibrium and haplotype analyses suggested that S1 had the strongest degree of association with COPD and pulmonary function abnormalities.

Conclusion: Five SNPs in ADAM33 were associated with COPD and lung function in long-term smokers. Functional studies will be needed to evaluate the biologic significance of these polymorphisms in the pathogenesis of COPD.
Background
Chronic Obstructive Pulmonary Disease (COPD) is a disorder that is characterized by progressive decline in lung function. The rate of decline in FEV1 in long term tobacco smokers who are susceptible to tobacco smoke is 3–5 fold that of the normal age related decline [1,2]. Nearly 90% of COPD is caused by long term cigarette smoking; however, only 25% of chronic tobacco smokers develop COPD [3]. Tobacco exposure in pack years correlates weakly with FEV1 [4] however, this relationship only partially explains reduced lung function in cigarette smokers with COPD. Furthermore, hyperinflation indicated by an enlarged residual volume is present in a subset of individuals with COPD while others manifest primarily a chronic bronchitic phenotype. Thus, host or genetic factors appear to predispose some individuals with tobacco exposure to the development of smoking related respiratory disease. Additionally, COPD tends to occur more frequently in smokers with a family history of obstructive airways disorders such as asthma and COPD. Thus, it has been suggested that asthma and COPD may share some predisposing factors and some clinical characteristics (The Dutch hypothesis [5-7]).

In 2002, van Eerdewegh and coworkers identified ADAM33 as a susceptibility gene for asthma and bronchial hyperresponsiveness on chromosome 20 p using positional cloning techniques [8]. While a number of studies have replicated this finding showing that ADAM33 is a susceptibility gene for asthma in different populations [9-12], some studies have not replicated these findings [13,14]. In addition variation in this gene was shown to be associated with an accelerated rate of decline in FEV1 in a longitudinal study of subjects with a clinical diagnosis of asthma [15] and with reduced lung function in a prospective birth cohort study [16]. In a longitudinal study from a general population, van Diemen and coworkers showed associations between SNPs in ADAM33 and annual decline in FEV1 in cigarette smokers who were compared to the larger population[17]. These studies did not comprehensively investigate the genetic variations observed in the ADAM33 gene and were not performed in a population of chronic cigarette smoker, the appropriate target population for studies of genetic susceptibility in COPD. Therefore, we comprehensively assessed ADAM33 variation (25 SNPs) in a large well characterized population of long term tobacco smokers and investigated the associations between these variations and COPD and spirometric variables.

Methods
Population and data
Subjects were recruited from a cohort of tradesmen referred for a work-related independent medical evaluation [18]. Referrals were come from trade unions as well as television and newspaper advertisements. Participants gave informed consent for their involvement in the genetic study, and the research protocol was reviewed and approved by the institutional review boards at Wake Forest University and Saint Louis University. As part of the referral process, an extensive questionnaire, a chest radiograph, and pulmonary function testing were obtained.

The questionnaire (additional file 1) detailed information about prior employment, smoking history, and personal and family medical histories. The questionnaire was self-administered prior to evaluation, and the physician examiner reviewed the entire questionnaire at the time of examination. Subjects were asked to quantify their cigarette smoking as packs per day, and ages of initiation and cessation of tobacco use. Chest radiographs were obtained and interpreted by a certified B-reader. Chest radiograph abnormalities were quantified according to the International Labor Organization (ILO) scoring system [19]. Lung function was measured at a variety of accredited hospital pulmonary function laboratories using equipment available at those sites. Pulmonary function testing was performed according to American Thoracic Society published guidelines [20]. Residual volume (RV) using He dilution was measured in a subset of subjects (FVC ≤ 80% predicted) to confirm the presence of restriction or hyperinflation [21]. Prebronchodilator spirometric data was used in the analysis.

For the current study, subjects over 50 years of age with a greater than or equal to 20 pack-year history of cigarette smoking were included in the analysis. We did not genotype any subject who was not a smoker or smoked less than 20 pack-years. The presence of evident occupational exposure induced lung disease (ILO scores greater than 1/89 subjects), mesothelioma, and an anticipated survival of less than one year secondary to active cancer, or other chronic diseases (226 subjects) were exclusion criteria.

COPD phenotype
The COPD phenotype, is a composite variable based on the GOLD guidelines [21]. However, to avoid a possible misclassification in the analyses, we classified COPD cases by using more stringent criteria. COPD was defined as an FEV1/FVC ratio < 70% and percent-predicted (pp)FEV1 < 75% (GOLD guideline criteria for stage 2 and above: FEV1/FVC ratio < 70% and ppFEV1 < 80%). Controls had an FEV1/FVC ratio ≥ 70% and ppFEV1 ≥ 80%. Subjects who fell into the category with FEV1/FVC ratio ≥ 70% and ppFEV1 < 80%, or FEV1/FVC ratio < 70% and ppFEV1 ≥ 75%, unclassified smokers, were excluded from categorical analyses (COPD vs. unaffected smokers) but included in additional analyses of continuous variables (quantitative traits: ppFEV1, FVC, FEV1/FVC ratio and ppFEF25–75).
Genotyping method
To further characterize the ADAM33 gene, we genotyped the target population for 25 SNPs in the gene chosen based on the Hapmap data and supplemented by SNPs reported in previous studies (25 SNPs). SNP genotyping was performed using the MassARRAY SNP genotyping system (Sequenom, Inc., San Diego CA) which utilizes a primer extension assay followed by mass spectrometry for oligonucleotide size determination. PCR and extension primers were designed using SpectroDesigner software (Sequenom, Inc.) and reactions were performed according to the manufacturer’s instructions. Genotypes were scored automatically using the SpectroTyper software (Sequenom, Inc.), and checked with quality control samples (i.e., duplicate DNA samples, negative controls) manually. All polymorphisms were assessed to determine if the observed genotype frequencies were consistent with Hardy-Weinberg equilibrium using Chi-square tests. Pairwise marker-linkage disequilibrium was estimated using Lewontin’s D’ statistic and $r^2$ [22].

Data analysis
We included 19 SNPs in ADAM33 that had a MAF $\geq 0.05$. The data analysis was performed in two stages. In the first stage we evaluated the association between the SNPs and COPD assuming an additive genetic model. In the next step we explored their relationship between the SNPs that reached a nominal statistical significance (p value < 0.05) in the first step, with pulmonary function measurements. We combined minor allele homozygotes with heterozygotes at this step as they were either absent or had very low frequencies. As we considered the second step in the analysis to be exploratory and because of the fact that COPD and pulmonary function measurements are highly correlated we corrected for multiple comparison testing based on our analysis in the first step. Therefore the Bonferroni corrected p-value was calculated as 0.05/19 (0.0026).

The association between ADAM33 genotypes and COPD having unaffected smoking as controls was evaluated by Logistic regression. We controlled for sex, age and pack-years smoked. To test for association we used Chi-square test for trend, assuming that the risk of the heterozygote genotype is between the risks of the major and the minor homozygote genotypes: additive genetic model. Generalized linear models (linear regression), adjusted for sex, age and pack-years smoked were used to test the associations between SNPs and the pulmonary function measurements: pp (percent predicted) FEV$_1$, ppFVC, FEV$_1$/FVC ratio, ppFEF$_{25-75}$ and percent predicted residual volume (ppRV). In the quantitative trait analyses for each SNP, we combined the heterozygote genotype with the minor homozygote genotype as they showed a similar effect in primary analysis. Statistical analysis was performed using SAS software (SAS Institute, Cary, N.C.).

Haplotype analysis for the SNPs genotyped was performed using a 3 SNP sliding window approach. Tests for association between haplotypes and COPD were performed using a score test as implemented in the computer program HAPLO.SCORE http://mayoresearch.mayo.edu/mayo/research/schaid_lab/upload/README.haplo.stats [23].

Results
Of the 880 subjects genotyped 97% of the subjects were men. Of these, 281 fell into the group excluded from categorical analyses (FEV$_1$/FVC ratio $\geq 70\%$ and ppFEV$_1$ < 80% or FEV$_1$/FVC ratio < 70% and ppFEV$_1$ $\geq 75\%$). The clinical characteristics of the groups with COPD, unaffected smoking controls and the unclassified cigarette smokers are shown in Table 1. They differed by FEV$_1$, FEV$_1$/FVC ratio and ppFEV$_1$, because of the phenotype definition. Subjects with COPD were slightly older (67.3 vs. 64.4) and smoked 58.6 pack years compared with 45.9

|                  | UNAFFECTED SMOKERS (ppFEV$_1$ $\geq$ 80 and FEV$_1$/FVC ratio($\%$) $\geq$ 70, n = 311) | COPD (ppFEV$_1$ < 75 and FEV$_1$/FVC ($\%$) < 70, n = 287) | Unclassified* n = 281 |
|------------------|---------------------------------------------------------------------------------|----------------------------------------------------------|-----------------------|
| pack years       | 45.9, 24.7                                                                      | 58.6, 31.1                                               | 55.3, 28.3            |
| Age              | 64.4, 10.0                                                                      | 67.3, 8.0                                                | 66.1, 9.4             |
| FEV$_1$ (L/sec)  | 3.1, 0.3                                                                       | 1.7, 0.6                                                 | 2.5, 0.53             |
| ppFEV$_1$        | 94.7, 10.1                                                                      | 53.5, 14.0                                               | 75.9, 12.9            |
| FEV$_1$/FVC (%)  | 78.3, 6.0                                                                       | 55.3, 10.8                                               | 52.4, 17.7            |
| ppFEF$_{25-75}$  | 85.5, 21.6                                                                      | 26.6, 13.4                                               | 71.1, 7.73            |
| % male           | 95.8                                                                            | 97.2                                                     | 98.2                  |

Of 880 Caucasian who smoked $\geq$ 20 pack years and were older than 50 years, 281 fell into the group excluded from categorical analyses (FEV$_1$/FVC ratio $\geq 70\%$ and ppFEV$_1$ < 80% or FEV$_1$/FVC ratio < 70% and ppFEV$_1$ $\geq 75\%$, unclassified). The analysis shows significant differences in age, and pack years smoked. ppFEV$_1$, FEV$_1$/FVC ratio, and ppFEF$_{25-75}$ were different due to selection criteria.

Chi-square for sex and ANOVA for the rest of the variables
pack years in unaffected smokers (Table 1). Smoking history in pack years correlated significantly \((p < 0.0001)\) with \(\text{ppFEV}_1\).

All genotype frequencies were consistent with Hardy-Weinberg equilibrium \((p \text{ value } > 0.05)\). We observed significant evidence \((p \text{ value } < 0.05)\) for association between 5 SNPs in ADAM33 (Q-1, rs6127096, \(p < 0.0028\); S1, rs391839, \(p < 0.0025\); S2, rs528557, \(p < 0.0326\); V-1, rs543749, \(p < 0.0011\) and V-4, rs2787094, \(p < 0.0068\), Table 2) and the composite variable for COPD (FEV1/FVC ratio < 70% and ppFEV1 < 75%, Figure 1). For these five SNPs, subjects homozygous for the common major allele were more frequent in the COPD group (Figure 1). Inclusion of potential confounders, age, sex, pack-years smoked, smoking status (current versus ex-smoker) and ILO score did not affect the results. After Bonferroni correction, only SNPs S1 and V-1 were significant \((p \text{ value } < 0.0026, \text{ based on 19 tests})\).

For Q-1, S1 and V-1, quantitative measurements, ppFEV1, FEV1/FVC ratio and ppFEF25–75 were significantly different between the common homozygous genotypes and other genotypes (dominant genetic model) (Table 3). S2 was associated only with FEV1/FVC ratio and V-4 was not associated with any of the quantitative measurements of pulmonary function (Table 3). Evaluation of all subjects, including the 281 subjects who were not characterized as cases and controls \((p \text{ value } < 0.0026)\), had information on percent predicted residual volume \((\text{ppRV})\). In these subjects the associations between ppRV and these SNPs showed a trend toward significance only for S1 \((\text{mean ppRV} = 132.1 \text{ for the common genotype, } n = 379, \text{ and ppRV} = 118.4 \text{ for the less common genotypes, } n = 74, p \text{ value } < 0.07)\).

Haplotype analysis for the 19 SNPs with a MAF > 0.05 was performed using a sliding window to include 3 SNPs at a time. Haplotypes in three regions of the gene were significantly associated with COPD (Figure 2). The second and the third regions included SNPs that showed significance in individual SNP analysis (Q-1-S1 and V-1-V4, respectively). Eight of the thirteen haplotypes were significantly associated with COPD included SNPs Q-1, S1 and S2. SNP S1 was present in six out of these eight SNPs. Linkage disequilibrium between the SNPs measured as \(D'\) and \(r^2\) are provided in supplemental materials (additional file 2 and additional file 3). In general, the correlation between SNPs was relatively low, but there were high LD measures between SNPs Q-1, S1 and S2 and V-1.

**Discussion**

In this study we genotyped 880 non-Hispanic whites with a long-term history of cigarette smoking for 25 SNPs in ADAM33. Cases were subjects who met GOLD criteria for stages 2, 3 and 4. The control group for these association studies included chronic cigarette smokers without evidence of airway obstruction. The analysis showed that 5 SNPs (Q-1, S1, S2, V-1 and V4) in ADAM33 were associated with COPD in these smokers. Consistent with these findings, subjects with the rare allele of Q-1, S1, and V-1 had significantly higher values for \(\text{ppFEV}_1\), FEV1/FVC ratio and ppFEF25–75 than did subjects with the common allele.

ADAM33, on chromosome 20p13, was identified by positional cloning and was shown to be associated with asthma and bronchial hyper-responsiveness [8]. Since that original publication several studies have replicated the association of ADAM33 with asthma [9,10,12,15,16,24-26]. Howard and coworkers showed an association of ADAM33 with asthma in ethnically diverse populations [9]. Since that report, replication studies in subjects derived from populations in Germany, the United Kingdom, Japan, Australia and the United States have been published [10,12,15]. However, in some studies the association between ADAM33 polymorphisms and asthma susceptibility could not be confirmed [13,14,27].

Previous studies have also demonstrated an association between ADAM33 polymorphisms and measurements of lung function. In a cohort of 200 asthma patients fol-
followed over 20 years, Jongepier and coworkers genotyped 8 SNPs in ADAM33 and found that the rare alleles of the SNPs S2, T1 and T2 of ADAM33 were associated with an excess decline in FEV1 [15]. On a population-based birth cohort, Simpson and coworkers reported that carriers of the rare allele of F+1 SNP had reduced lung function at age 3 years. When the recessive model was considered, SNPs F+1, S1, ST+5, and V4 showed association with reduced lung function at age 5 years. Using linkage disequilibrium mapping, they found evidence of a significant causal location between BC+1 and F1 SNPs, at the 5’ end of the gene. Four SNPs were associated with lower FEV1 (F+1, M+1, T1, and T2). They concluded that polymorphisms in ADAM33 predict impaired early-life lung function.

A relationship between ADAM33 variation and COPD has also been shown. In a Dutch general population including smokers and non-smokers, van Diemen and colleagues genotyped 1390 subject for 8 SNPs in ADAM33. They defined 186 subjects as COPD GOLD stage 2 or greater (FEV1/FVC ratio < 70% and ppFEV1 < 80%). This study showed that individuals homozygous for the minor alleles of SNPs S2 and Q-1 and heterozygous for SNP S1 had an excess annual decline in FEV1 compared to their respective wild type. They also found a significantly greater frequency of minor alleles of SNPs F+1, S1, S2, and T2 in subjects with COPD (n = 186) compared to the entire general population that included non-smokers. Using 111 COPD patients from this population, Gosman et al. suggested association between SNPs ST+5, T1 and T2, and S2 with airway hyper-responsiveness, higher numbers of sputum inflammatory cells and CD8 cells in bronchial biopsies. The Van Diemen study is the only previous study on the association between ADAM33 and COPD. As in Van Diemen’s report we saw associations between SNPs Q-1, S1 and S2 and COPD; however with opposite allele. Other differences between that study and the current report are the number of COPD subjects (186 versus 288), the type of control group for COPD (general population vs smokers) and the number of SNPs studied (8 vs 25). Indeed, we believe that the most appropriate control group for studies on COPD should consist of chronic cigarette smokers who are at risk for COPD and yet have normal lung function. To this end, the controls in this report have comparable exposure to tobacco smoke as the affected cases.

The five SNPs that reached statistical significance in our analyses (Q-1, S1, S2, V-1 and V4) were among SNPs that were reported to be significant in the initial report by Van Eerdewegh and coworkers. Furthermore, the allele frequency in both controls and cases are comparable between this report and Van Eerdewegh (cases having COPD and asthma, respectively, Table 4). Frequencies of

Table 2: Associations* between SNPs in ADAM33 gene and COPD

| SNP     | Genotype | COPD | Controls |
|---------|----------|------|----------|
|         | N  | %    | N  | %    | p value* |
| rs2853211 (IVS1_729) | GG | 16 | 5 | 20 | 6 | 0.4083 |
| rs4987245 (IVS1_379) | AA | 3 | 1 | 1 | 0 | 0.1522 |
| rs570269 (IVS2_488)  | GG | 14 | 0 | 5 | 1 | 0.736 |
| rs487377 (IVS2_1141) (BC+1) | AA | 15 | 3 | 1 | 1 | 0.0826 |
| rs2853210 (IVS2_421) | AA | 9 | 3 | 1 | 4 | 0.1519 |
| rs511898 (IVS6_66) (F+1) | AA | 35 | 12 | 44 | 14 | 0.0204 |
| rs3918395 (IVS13_35) (M+1) | GT | 67 | 24 | 74 | 24 | 0.8832 |
| rs612709 (IVS16_21) (Q-1) | TT | 4 | 1 | 5 | 2 | 0.0028 |
| rs3918396 (Ile710Val) (S1) | AA | 2 | 1 | 3 | 1 | 0.0025† |
| rs526557 (Gly717Gly) (S2) | CC | 17 | 6 | 27 | 9 | 0.0326 |
| rs2853209 (IVS19_181) | TT | 60 | 21 | 77 | 25 | 0.0921 |
| rs598418 (IVS19_384) | CC | 38 | 13 | 31 | 10 | 0.1062 |
| rs44707 (IVS19_427) (ST+4) | AA | 94 | 33 | 115 | 37 | 0.1554 |
| rs574174 (IVS19_959) (ST+7) | AA | 7 | 2 | 12 | 4 | 0.0731 |
| rs2280091 (Met738Thr) (T1) | CC | 6 | 2 | 5 | 1 | 0.8823 |
| rs678881 | GG | 19 | 7 | 12 | 4 |
S2, V-1 and V4 were also comparable to Howard et al [9]. However, the risk alleles in our study were opposite to what were reported by Simpson and van Diemen [16,17]. These five SNPs are confined to two regions in ADAM33 gene (one containing Q-1, S1 and S2 and the other containing V-1 and V4). SNPs Q-1, S1 and S2 are in a block and SNP V-1, although more than 2 kb apart, has high LD measurements ($D' = 1$ and $0.39 \leq r^2 \leq 0.90$) with the SNPs in this block. SNP V4 is neither in a block with its neighboring SNP V1 nor in LD with either of Q-1, S1 or S2. Furthermore, SNP V4 was not associated with any of the lung function measurements. With regard to location and function, SNPs Q-1 and V-1 are in intronic regions, S1 is a non-synonymous and S2 is a synonymous SNP. It is of importance that haplotype analysis showed that S1 was present in 6 out of 13 significant haplotypes. Three of the six haplotypes containing S1 had a frequency of more than 70%, unlike any other SNP. Additionally, S1 was the only SNP whose association with residual volume approached significance ($p < 0.07$) in a subset of the studied population. While it is possible that Q-1 and V-1 have some effect on mRNA splicing, we hypothesize that S1 accounts for the association with COPD. However, definitive identification of the specific SNP associated with COPD requires functional analysis.

There is some functional data on ADAM33 protein. For example, Foley et al [28] reported that the ADAM33 mRNA expression was significantly higher in both moderate and severe asthma compared with mild asthma and controls ($p < 0.05$). Additionally, immunostaining for ADAM33 was increased in the epithelium, submucosal cells, and smooth muscle in severe asthma compared with mild disease and controls and in bronchial bud during airway morphogenesis. ADAM33 is a disintegrin within the metalloproteinase family. Its association with fetal lung morphogenesis and accelerated rate of decline in FEV1 in adults suggests a role in airway remodeling. Hypothesized mechanisms include release or activation

### Table 2: Associations* between SNPs in ADAM33 gene and COPD (Continued)

| SNP        | Genotype | ppFEV1 | p value* | ppFVC | p value* | Ratio | p value* | ppFEF25–75 | p value* |
|------------|----------|--------|----------|-------|----------|-------|----------|------------|----------|
| rs612709   | CT+TT    | 78.62  | 0.0135   | 84.49 | 0.2610   | 69.88 | 0.0044   | 64.52      | 0.0015   |
| (Q-1)      | CC†      | 73.72  | 0.0132   | 83.36 | 0.3093   | 66.42 | 0.0122   | 55.00      | 0.0012   |
| rs3918396  | AG+AA    | 79.08  | 0.0256   | 83.85 | 0.2883   | 70.35 | 0.0068   | 64.84      | 0.0079   |
| (S1)       | GG†      | 74.17  | 0.0143   | 83.93 | 0.2710   | 66.69 | 0.0112   | 56.00      | 0.0019   |
| rs528557   | CG+CC    | 75.94  | 0.2342   | 84.91 | 0.8372   | 68.38 | 0.0425   | 59.51      | 0.1131   |
| (S2)       | GG†      | 74.26  | 0.1571   | 83.49 | 0.6225   | 66.42 | 0.1329   | 55.80      | 0.1594   |
| rs543749   | CA+AA    | 79.08  | 0.0083   | 85.20 | 0.2085   | 69.96 | 0.0050   | 65.17      | 0.0009   |
| (V-1)      | CC†      | 73.57  | 0.0057   | 83.42 | 0.2211   | 66.40 | 0.0116   | 54.76      | 0.0004   |
| rs2787094  | CG+GG    | 76.50  | 0.1501   | 85.14 | 0.3591   | 68.32 | 0.1229   | 60.54      | 0.0568   |
| (V4)       | CC†      | 73.92  | 0.1697   | 83.61 | 0.5695   | 66.63 | 0.1756   | 55.32      | 0.0344   |

*COPD: Chronic Obstructive Pulmonary Disease; defined by an FEV1/FVC ratio < 70% and ppFEV1 < 75% (n = 287). Control group were smokers with an FEV1/FVC ratio ≥ 70% and ppFEV1 ≥ 80% (n = 311).

### Table 3: Estimated* mean pulmonary function measurements for genotypes of SNPs in ADAM33 gene that were associated with COPD.

| SNP        | Genotype | ppFEV1 | p value* | ppFVC | p value* | Ratio | p value* | ppFEF25–75 | p value* |
|------------|----------|--------|----------|-------|----------|-------|----------|------------|----------|
| rs612709   | CT+TT    | 78.62  | 0.0135   | 84.49 | 0.2610   | 69.88 | 0.0044   | 64.52      | 0.0015   |
| (Q-1)      | CC†      | 73.72  | 0.0132   | 83.36 | 0.3093   | 66.42 | 0.0122   | 55.00      | 0.0012   |
| rs3918396  | AG+AA    | 79.08  | 0.0256   | 83.85 | 0.2883   | 70.35 | 0.0068   | 64.84      | 0.0079   |
| (S1)       | GG†      | 74.17  | 0.0143   | 83.93 | 0.2710   | 66.69 | 0.0112   | 56.00      | 0.0019   |
| rs528557   | CG+CC    | 75.94  | 0.2342   | 84.91 | 0.8372   | 68.38 | 0.0425   | 59.51      | 0.1131   |
| (S2)       | GG†      | 74.26  | 0.1571   | 83.49 | 0.6225   | 66.42 | 0.1329   | 55.80      | 0.1594   |
| rs543749   | CA+AA    | 79.08  | 0.0083   | 85.20 | 0.2085   | 69.96 | 0.0050   | 65.17      | 0.0009   |
| (V-1)      | CC†      | 73.57  | 0.0057   | 83.42 | 0.2211   | 66.40 | 0.0116   | 54.76      | 0.0004   |
| rs2787094  | CG+GG    | 76.50  | 0.1501   | 85.14 | 0.3591   | 68.32 | 0.1229   | 60.54      | 0.0568   |
| (V4)       | CC†      | 73.92  | 0.1697   | 83.61 | 0.5695   | 66.63 | 0.1756   | 55.32      | 0.0344   |
of growth factors and facilitation of migration of fibroblasts or inflammatory cells through the matrix. The trend towards association of ADAM33 with RV is consistent with a role for ADAM33 in airway remodeling that will require study with larger numbers to confirm.

Unique strengths of this study were having the proper control subjects, i.e. smokers susceptible to develop COPD, and a thorough SNP panel. A limitation of our study was that we did not formally test for population stratification.

In summary, we evaluated a well characterized group of cases and controls who were long term tobacco smokers and comprehensively genotyped them for ADAM33 variation. Five polymorphisms: Q-1, S1, S2, V-1 and V4 in ADAM33 were associated with COPD. When we applied Bonferroni correction, only SNPs S1 and V-1 hold statistical significance. SNPs Q-1, S1 and S2 were within 500 bp and in a haplotype block. SNP V-1 was 2 kb apart from this block but revealed high linkage disequilibrium measurements with this block. These four SNPs (Q-1, S1, S2 and V-1) were also associated with lung function measurements. SNP V4 was neither linked to the other four SNPs nor was it associated with lung function. Based on these data and the fact that S1 is a non-synonymous SNP (Isoleucine → Valine), studies to assess the functional significance of this amino acid change in the ADAM33 protein COPD, and a thorough SNP panel. A limitation of our study was that we did not formally test for population stratification.

Table 4: Comparison of minor allele frequencies between the current study and the original report on ADAM33

| SNP       | COPD Controls | COPD Cases | Van Eerdewegh, All Controls | Van Eerdewegh, All Cases |
|-----------|---------------|------------|-----------------------------|--------------------------|
| Q-1 (rs612709) | 0.168         | 0.105      | 0.150                       | 0.088                    |
| S1 (rs3918396) | 0.120         | 0.070      | 0.105                       | 0.054                    |
| S2 (rs528557) | 0.304         | 0.250      | 0.262                       | 0.200                    |
| V-1 (rs543749) | 0.159         | 0.100      | 0.148                       | 0.076                    |
| V4 (rs2787094) | 0.257         | 0.195      | 0.233                       | 0.164                    |

Figure 2
Haplotype analysis using a sliding window of three SNPs at a time for 19 SNPs with a MAF ≥ 5% in ADAM33 gene, having COPD as the phenotype of interest.
and other functional assays are necessary to understand the biologic basis for the association of ADAM33 variation and obstructive pulmonary diseases.

### Competing interests
The authors declare that they have no competing interests.

### Authors' contributions
JO and DAS established the population. ERB, DAM and JO planned the current study. AS and DAM designed and conducted the statistical analyses. AS compiled the results. JOP planned the current study. AS and DAM designed and conducted the statistical analyses. AS compiled the results. GAH and SLZ performed genotyping. All authors contributed in writing the manuscript and approved the final version.

### Additional material

**Additional File 1**  
Asbestos screening. The questionnaire that was used to obtain information on study subjects.  
Click here for file  
[http://www.biomedcentral.com/content/supplementary/1465-9921-10-21-S1.doc]

**Additional File 2**  
D-prime. The figure represents Linkage disequilibrium (D') between ADAM33 SNPs.  
Click here for file  
[http://www.biomedcentral.com/content/supplementary/1465-9921-10-21-S2.doc]

**Additional File 3**  
R-prime. The figure represents Linkage disequilibrium (r²) between ADAM33 SNPs.  
Click here for file  
[http://www.biomedcentral.com/content/supplementary/1465-9921-10-21-S3.doc]

### Acknowledgements
This study was funded in part by The Selikoff Fund for Environmental and Occupational Cancer Research, Saint Louis University.

### References

1. Fletcher C, Peto R: The natural history of chronic airflow obstruction. British medical journal 1977, 1(6077):1645-1648.
2. Anthonisen NR, Connolly JE, Kiley JP, Alarcon MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O'Hara P, et al.: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. Jama 1994, 272(19):1497-1505.
3. Lokie A, Lange P, Scharling H, Fabricius P, Vestbo J: Developing COPD: a 25 year follow up study of the general population. Thorax 2006, 61(11):935-939.
4. Sadeghnejad A, Meyers DA, Botzai M, Sterling DA, Bleecker ER, Ohar J: IL13 Promoter Polymorphism -1112C/T Modulates the Adverse Effect of Tobacco Smoking on Lung Function. American journal of respiratory and critical care medicine 2007.
5. Bleecker ER: Similarities and differences in asthma and COPD. The Dutch hypothesis. Chest 2004, 126(2 Suppl):935-93S. discussion 1595–1615
6. Meyers DA, Laij MJ, Lange L: Genetics of asthma and COPD. Similar results for different phenotypes. Chest 2004, 126(2 Suppl):1055-105S. discussion 1595–1615
7. Postma DS, Boezen HM: Rationale of the Dutch hypothesis. Allergy and airway hyperresponsiveness as genetic factors and their interaction with environment in the development of asthma and COPD. Chest 2004, 126(2 Suppl):96S-104S. discussion 1595–1615
8. Van Eerdegewegh P, Little RD, Dupuis J, Del Mastro RG, Falls K, Simon J, Torrey D, Pandit S, McKenny J, Braunschweiger K, et al.: Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness. Nature 2002, 418(6896):426-430.
9. Ohlendorf TD, Postma DS, Jongepeer H, Moore WC, Koppelman GH, Zheng SL, Xu J, Bleecker ER, Meyers DA: Association of a disintegrin and metalloproteinase 33 (ADAM33) gene with asthma in ethnically diverse populations. The Journal of allergy and clinical immunology 2003, 112(4):717-722.
10. Smajska J, Halapi E, Bijnens H, Wheatley C, Kristinsson S, Upmanyu R, Stefansson K, Hakonarson H, Hall IP: Contribution of ADAM33 polymorphisms to the population risk of asthma. Thorax 2005, 60(4):274-276.
11. Holloway JW, Keith TP, Davies DE, Powell R, Hantzhi MH, Holgate ST: The discovery and role of ADAM33, a new candidate gene for asthma. Expert reviews in molecular medicine [electronic resource] 2004, 6(17):1-12.
12. Werner M, Herbon N, Gohike H, Altmuller J, Knapp M, Heinrich J, Wijst M: Asthma is associated with single-nucleotide polymorphisms in ADAM33. Clin Exp Allergy 2004, 34(12):263-116.
13. Lee JH, Park HS, Park SW, Jang AS, Uh ST, Rhim T, Park CS, Hong SJ, Holgate ST, Holloway JW, et al.: ADAM33 polymorphism: association with bronchial hyper-responsiveness in Korean asthmatics. Clin Exp Allergy 2004, 34(6):860-865.
14. Lind DL, Choudhry S, Ung N, Ziv E, Avila PC, Salari K, Ha C, Lovins EG, Coyle NE, Nazario S, et al.: ADAM33 is not associated with asthma in Puerto Rican or Mexican populations. American journal of respiratory and critical care medicine 2003, 168(11):1312-1316.
15. Jongepier H, Boezen HM, Dijkstra A, Howard TD, Vonk JM, Koppelman GH, Zheng SL, Meyers DA, Bleecker ER, Postma DS: Polymorphisms of the ADAM33 gene are associated with accelerated lung function decline in asthma. Clin Exp Allergy 2004, 34(5):757-760.
16. Simpson A, Maniatis N, Jury F, Cakebread JA, Lowe LA, Holgate ST, Woodcock A, Ollier WE, Collins A, Custovic A, et al.: Polymorphisms in a disintegrin and metalloproteinase 33 (ADAM33) predict impaired early-life lung function. American journal of respiratory and critical care medicine 2005, 172(1):53-60.
17. van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Schouten JP, Wjst M: The discovery and role of ADAM33, a new candidate gene for asthma. Am J Respir Crit Care Med 2002, 165(4):329-333.
18. van Diemen CC, Postma DS, Vonk JM, Bruinenberg M, Schouten JP, Wjst M: The discovery and role of ADAM33, a new candidate gene for asthma. Am J Respir Crit Care Med 2002, 165(4):329-333.
19. Ohar J, Sterling DA, Bleecker E, Donohue J: Changing patterns in asbestos-induced lung disease. Chest 2004, 125(2):744-753.
20. Labour OI: ILO international classification of radiographs of pneumoconioses: occupational safety and health series, No. 22 revised. In Geneva, Switzerland; 1980.
21. Standardization of Spirometry, 1994 Update: American Thoracic Society. American journal of respiratory and critical care medicine 1995, 152(3):107-1136.
22. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. American journal of respiratory and critical care medicine 1995, 152(3):107-1136.
23. Lewontin RC: The Interaction of Selection and Linkage. II. Optimum Models. Genetics 1964, 50:757-782.
24. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score tests for association between traits and haplotypes when linkage phase is ambiguous. American journal of human genetics 2002, 70(2):425-434.
25. Schedel M, Depner M, Schoen C, Weiland SK, Vogelberg C, Niggemann B, Lau S, Illig T, Klop N, Wahn U, et al.: The role of polymorphisms in ADAM33, a disintegrin and metalloproteinase 33, in childhood asthma and lung function in two German populations. Respiratory research 2006, 7:91.
associated with asthma susceptibility in a Japanese population. Clin Exp Allergy 2006, 36(5):602-608.

26. Kedda MA, Duffy DL, Bradley B, O’Hehir RE, Thompson PJ: ADAM33 haplotypes are associated with asthma in a large Australian population. Eur J Hum Genet 2006, 14(9):1027-1036.

27. Raby BA, Silverman EK, Kwikiskowski DJ, Lange C, Lazarus R, Weiss ST: ADAM33 polymorphisms and phenotype associations in childhood asthma. The Journal of allergy and clinical immunology 2004, 113(6):1071-1078.

28. Foley SC, Mogas AK, Olivenstein R, Fiset PO, Chakir J, Bourbeau J, Ernst P, Lemiere C, Martin JG, Hamid Q: Increased expression of ADAM33 and ADAM8 with disease progression in asthma. The Journal of allergy and clinical immunology 2007, 119(4):863-871.

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright